摘要
目的:系统评价莫西沙星与左氧氟沙星分别治疗慢性阻塞性肺疾病加重期(AECOPD)的临床疗效与安全性,为临床应用提供更优化的方案。方法:计算机检索中国学术期刊全文数据库(CNKI)、万方数据库(WANFANG DATA)、中国生物医学文献数据库,检索时间为2002年至2013年。纳入比较莫西沙星(试验组)与左氧氟沙星(对照组)治疗AECOPD的随机对照试验(RCT),排除不符合的文献后,使用RevMan5.0软件进行Meta分析。结果:共纳入7个RCT,共计409例慢性阻塞性肺疾病(COPD)患者。在总有效率方面,试验组高于对照组(OR=2.79,95%CI=1.56～5.01,P=0.000 6);在细菌清除率方面,试验组显著高于对照组(OR=2.27,95%CI=1.23～4.19,P=0.009)。409例患者中,试验组有13例发生不良反应,对照组有22例。结论:莫西沙星治疗AECOPD的总有效率与细菌清除率均显著高于左氧氟沙星,且不良反应较少,可以考虑用莫西沙星代替左氧氟沙星用于AECOPD的治疗。
OBJECTIVE：To evaluate the efficacy and safety of moxifloxacin vs. levofloxacin for acute exacerbation of chronic obstructive pulmonary disease （AECOPD） so as to provide a more optimal scheme in clinical application. METHEDS： The databases including CNK, WanFang Data and Chinese Biomedical Literature Database were electronically searched （searching time： from 2002 to 2013）. The randomized controlled trials （RCTs） on moxifloxacin （trial group） vs. levofloxacin （control group） in the treatment of acute exacerbations of chronic obstructive pulmonary disease （COPD） meeting the inclusion criteria were included and meta-analysis was performed using RevMan 5. 0 software. RESULTS ： Seven RCTs involving 409 patients with COPD were included. The results of meta-analysis showed that trial group was significantly superior to control group in total effective rate [ OR =2. 79, 95% CI （ 1.56 -5.01 ）, P -- 0. 000 6]; the bacterial clearance rate in trial group was also higher than in the control group [ OR = 2. 27, 95% CI （ 1.23 - 4. 19）, P = 0. 009 ]. Of the total 409 patients, 13 cases in the trial group vs. 22 cases in control group presented with adverse reactions. CONCLUSION： Treatment of AECOPD with Moxifloxacin resulted in significantly higher effective rate and higher bacterial clearance rate yet less adverse drug reactions than with levofloxacin. Hence it is advisable to consider moxifloxacin as a substitute for levofloxacin in the treatment of AECOPD.
出处
《中国医院用药评价与分析》
2013年第7期594-598,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
